QUCY 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• We are a technology company focused on developing intelligent, scalable platforms that integrate artificial intelligence (“AI”) and quantum computing to power next-generation control systems for unmanned vehicles, aerial vehicles and underwater vehicles, such as drones, self-driving cars and robotic…

• Our platforms are designed to address the fundamental limitations of classical computing approaches to autonomous vehicle control, specifically the inability to solve high-dimensional, multi-objective optimization problems in real time. By pairing AI-driven adaptive perception and decision-making wi…

• Our core mission is to accelerate the convergence of AI and quantum technologies to deliver safer, more capable, and more efficient autonomous systems for defense, commercial logistics, disaster response, and critical infrastructure operations. We believe this convergence represents a significant te…

• Historically we had focused on developing and selling in-vitro diagnostic tests for the early detection of cancer. During 2025 and early 2026, our legacy ColoAlert product was marketed and sold in European markets. Since 2020, we have also been developing both a blood and stool test for the early de…

• In February 2026, the Company’s Board of Directors made the decision to close our colorectal cancer line of business to focus on the pancreatic screening line of business.

相对上期删除的文字 · 来源:10-Q · 2026-05-15

• Historically we have focused on developing and selling in-vitro diagnostic (“IVD”) tests for the early detection of cancer. During 2025 and early 2026, our legacy ColoAlert product was marketed and sold in European markets. Since 2020, we have been developing both a blood and stool test for the earl…

• In February 2026, the Board made the decision to close our colorectal cancer line of business to focus on the pancreatic screening line of business. As a result of that decision the Board marketed for sale the two groups of assets related to the ColoAlert and NextGen product lines, which were primar…

• In February 2026, the Board made the decision to close the Company’s colorectal cancer line of business to focus on the pancreatic screening line of business. As a result of that decision, the Board marketed for sale the two groups of assets related to the ColoAlert and NextGen product lines, includ…

• Business Highlights, Known Trends, Events, and Uncertainties

• During the three months ended March 31, 2026, the Company continued to advance its diagnostic portfolio, focused on its pancreatic screening product line under development, including being accepted to present the clinical results for our feasibility studies at American Association for Cancer Researc…

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• Although we are a smaller reporting company and are not required to provide this information, the following risk factors supplement the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2025 and in the risk factor disclosure included in our Current Report on Fo…

• We may not successfully execute our strategic transition into AI-enabled autonomous systems, drone technologies, and quantum-related applications.

• Our current business strategy involving AI-enabled autonomous systems, drone technologies, cybersecurity applications, quantum optimization technologies, and defense-related operational systems is relatively new and evolving. We have entered into license arrangements and acquisition transactions int…

• Our business depends on rights obtained from third-party license arrangements, and those arrangements may not produce commercially viable products or may limit our flexibility.

• We have entered into license arrangements with third parties, including BP United and Project LightShift, to support our development and commercialization plans. The value of these arrangements depends on, among other things, the validity, enforceability, scope, technical performance, development st…

相对上期删除的文字 · 来源:10-Q · 2026-05-15

• Although as a Smaller Reporting Company we are not required to provide this information, we refer you to the section entitled “Item 3 -- Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025 filed on March 31, 2026.